Rofecoxib (VIOXX^®)

Health Canada is committed to ensuring that stakeholders and the general public remain up to date on current developments, information, and issues pertaining to marketed health products. Information recently made available under the Access to Information Act about rofecoxib (VIOXX^®) is presented here for all interested stakeholders and the general public. In some instances, information considered exempt from the right of access has been removed from the records.

For the current status on this product, please click here

Users of this repository have access to the following information:

• Notice of Compliance
• Current Official Canadian Product Monograph
• Product Data Related to Original Market Authorization, Released Through the "Access to Information Act"
• Merck Frosst Canada's Statement on Benefits and Risks of Using VIOXX^®
• Health Canada Reports on Benefits and Safety of Selective COX-2 Inhibitor NSAIDs
• Questions for the Expert Advisory Panel on the Safety of Selective COX-2 Inhibitor NSAIDs

The repository provides information presented in HTML, and files provided in Portable Document Format (PDF). While all introductory information is provided in both English and French, the PDF files themselves (excluding those for the Canadian Product Monograph) are only provided in English. Because the information originates with an organization that is not subject to the Official Languages Act, it is available on this site only in the language in which it was written.

VIOXX^® is a registered trademark of Merck Frosst Canada Ltd.